THE MCMANUS GROUP for GILEAD SCIENCES, INC.
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Federal program coverage, access and reimbursement issues for Hepatitis C, HIV, and oncology products, including proposed rule "Medicare Program; Hospital Inpatient Prospective Payment Systems for Acute Care Hospitals and the Long-Term Care Hospital Prospective Payment System and Proposed Policy Changes and Fiscal Year 2020 Rates; Proposed Quality Reporting Requirements for Specific Providers; Medicare and Medicaid Promoting Interoperability Programs Proposed Requirements for Eligible Hospitals and Critical Access Hospitals" (84 FR 19158, 42 CFR 412).
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Budget/Appropriations BUD
Funding for HCV and public health activities via appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Health Issues HCR
Pharmaceutical policy as it relates to payments under the 340B program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MCMANUS | — |
| BARRETT THORNHILL | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.